Michael McLane

Michael McLane practices at St. Luke's Hospital - Carbon Campus in Lehighton, Pennsylvania, part of St. Luke's University Health Network.

Michael McLane's NPI, 1669853271, was assigned on June 10, 2015. Michael McLane graduated from Philadelphia College of Osteopathic Medicine in 2015. Michael McLane holds Pennsylvania license OS021324.

Michael McLane's primary practice is St. Luke's Hospital - Carbon Campus, at 500 St Luke's Drive, Lehighton, PA 18235 in Carbon County. The practice phone is (610) 377-7001.

Michael McLane's primary practice is St. Luke's Hospital - Carbon Campus in Lehighton, Pennsylvania, part of St. Luke's University Health Network. Michael McLane is also affiliated with St. Luke's University Hospital - Bethlehem Campus. The medical group on file is St. Luke's South Mountain Family Practice. Dmand AI also links Michael McLane to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Michael McLane practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Michael McLane's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Michael McLane is licensed in Pennsylvania.

CMS data shows 3,619 Medicare services from Michael McLane across 23 procedure codes in 2024, for 1,462 Medicare patients. Medicare paid $136,501 for them.

CMS counts 1,462 Medicare patients who saw Michael McLane in 2024. The largest group is 65 to 74, with 589 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Michael McLane's median patient age at 72, with 49% women.

In 2024, Michael McLane wrote 3,699 Medicare Part D claims for 431 patients. 84% of them were for generic drugs. CMS names the drug for 3,524 of them, across 37 drugs with 11 or more claims each, at $465,842 in total drug cost. In 2023, CMS named 2,829 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Michael McLane for performance year 2024, reported through an alternative payment model (APM). Michael McLane accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Michael McLane as offering telehealth.

Dmand AI links 22 papers to Michael McLane, published from 2011 to 2022. 2019 was the busiest year, with 7. The most frequent topics are Disease Models, Animal, Inflammation and Lipopolysaccharides. Michael McLane has published most often in Am J Reprod Immunol. Michael McLane's most frequent co-authors are Irina D. Burd, MD, PhD, Jun Lei, MD and Maide Ozen, MD.

CMS Open Payments shows 26 general payments to Michael McLane from 12 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 86% of the total. Janssen Pharmaceuticals, Inc paid the most, $683.

Michael McLane graduated from Philadelphia College of Osteopathic Medicine in 2015.